Featured Conference
2nd Annual Aligning Medical Affairs and Marketing
Optimal Drug Promotion Through Innovation and Collaboration
April 26-28, 2004 * Princeton, NJ
Until recent months, the divisions of Medical Affairs and Marketing have functioned as two separate entities, rarely relying upon one another to perform their jobs. With the release of the Compliance Program Guidance for Pharmaceutical Manufacturers by the Office of the Inspector General (OIG), as well as other regulatory mandates, increased commercialism and liability, a harmonious partnership between the two areas is no longer a choice, but a necessity, to ensure optimum exposure for the organization in a compliant and streamlined manner.
Furthermore, previously under-utilized and/or unrecognized opportunities for innovative drug and manufacturer promotion must now be realized collectively within the collaboration of Medical Affairs and Marketing or risk non-compliance. The companies who best understand how to implement novel and collaborative programs within the letter of the law will realize greater success resulting in an increase in drug acceptance and name brand recognition.
Although simple in concept, instituting proper alignment between Medical Affairs and Marketing divisions is not a clear-cut or simple task. This conference offers a guideline on best practices to align Medical Affairs and Marketing, thus ensuring optimal and compliant drug promotion. Benefit from the experience of our distinguished speaker faculty as they share practical information on todays critical topics including:
- Successful partnerships between Medical Affairs and Marketing
- Current messages from the Department of Justice
- Utilizing call centers to outsource your medical information
- Increasing customer focus through strategic lifecycle management
- Marketing the mature brand
- Best practices for constructing CME programs
- The evolution of a comprehensive Investigator Initiated Trial (IIT) program
- Effective organization of a successful publications program
- Managing the risks of off-label usage
- Strategic alignment at pre-launch, launch and post-launch
- Utilizing Patient Level Data (PLD) as a marketing asset
- Effective communications between pharmaceuticals and managed care
- Seamless expansion of a Medical Science Liaison (MSL) program
- Compliant brand marketing of pharmaceutical products
- Utilizing pharmacoeconomics to construct marketing messages
- …and more
Plus take advantage of our pre-conference workshops:
- Managing Medical Science Liaisons
- How to Select and Collaborate With CME Providers
For more information about registering for this conference, visit the conference site at www.pharmedassociates.com/business.asp#p148
